All In Biotech

Drug Trial Radar · NCT01065454

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-center Study to Evaluate the Hemodynamic Effects of Riociguat (BAY 63-2521) as Well as Safety and Kinetics in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

Last checked: Nov 20, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 202 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

202

Actual

Start

Apr 14, 2010

Primary completion

Jun 6, 2012

Study completion Jul 23, 2025

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Feb 9, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction

Conditions

  • Hypertension, Pulmonary
  • Ventricular Dysfunction, Left

Interventions

  • Riociguat (Adempas, BAY63-2521)Drug

    up to 2 mg three times a day (increasing from 0.5 to 1 to 2 mg)

  • Riociguat (Adempas, BAY63-2521)Drug

    up to 1 mg three times a day (increasing from 0.5 to 1 mg)

  • Riociguat (Adempas, BAY63-2521)Drug

    fixed 0.5 mg three times a day

  • PlaceboDrug

    Placebo three times a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pulmonary Artery Mean Pressure (PAPmean) at Rest - Change From Baseline to Week 16Time frame: Baseline and visit 6 (16 weeks)

Locations

83 sites in 18 countries. Site status is shown where the registry gives one.

  • Site not named

    Los Angeles, California

  • Site not named

    San Diego, California

  • Site not named

    Torrance, California

  • Site not named

    Westminster, California

  • Site not named

    Miami, Florida

  • Site not named

    Iowa City, Iowa

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Rochester, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Fairfield, Ohio

  • Site not named

    Falls Church, Virginia

  • Site not named

    Milwaukee, Wisconsin

  • Site not named

    Sydney, New South Wales, Australia

  • Site not named

    Herston, Queensland, Australia

  • Site not named

    Melbourne, Victoria, Australia

  • Site not named

    Vienna, State of Vienna, Austria

  • Site not named

    Innsbruck, Tyrol, Austria

  • Site not named

    Aalst, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Edmonton, Alberta, Canada

  • Site not named

    Vancouver, British Columbia, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Québec, Quebec, Canada

  • Site not named

    Beijing, China

  • Site not named

    Shanghai, China

  • Site not named

    Shanghai, China

  • Site not named

    Brno, Czechia

  • Site not named

    Olomouc, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Aarhus N, Denmark

  • Site not named

    Bron, France

  • Site not named

    Lille, France

  • Site not named

    Nantes, France

  • Site not named

    Pessac, France

  • Site not named

    Rouen, France

Showing 40 of 83 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.